Clinical Trial

A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

Name: A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia — clinical trial record (NCT07175493)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-09-08.

Status change: Not Yet Recruiting → Recruiting 2025-12-09

Trial Details

NCT Number	NCT07175493
Lead Sponsor	Keymed Biosciences Co.Ltd
Conditions	Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome
Enrollment	158 participants
Start Date	2025-11-18
Primary Completion	2027-11-18 (estimated)
Study Completion	2028-11-18 (estimated)
Updated on ClinicalTrials.gov	2025-12-17